Key Drivers
- Strong Liquidity
- Volatile Earnings
- Accumulated Losses
AIAI Summary
TBPH should now be viewed primarily as a merger-arbitrage/value-realization trade—not a standalone biotech growth story—because the $17.00 cash deal caps upside and any extra return depends on a speculative CVR, so the actionable focus is on closing certainty, spread capture, and litigation/CVR risk rather than operating momentum.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Volatile Earnings
- •Accumulated Losses
TBPH has a very strong balance sheet and cash generation, but its recent loss, volatile profitability, and large accumulated deficits make the earnings profile less dependable.
Price Behavior
Key Price Behavior Insights:
- •Uptrend intact
- •Late pullback
- •Support test
TBPH's trend remains positive over the last month, but fading momentum after the late-June peak means it must hold $16.50–$16.60 and reclaim $17.00/$17.63 to resume the upside.
The late-June breakout attempt faded into a short pullback after the 2026-06-26 peak
Sentiment & News
Key News Insights:
- •$17 Buyout
- •CVR Upside
- •Shareholder Scrutiny
Theravance Biopharma agreed to be acquired by Zymeworks for $17.00 per share in cash plus a CVR tied to ampreloxetine monetization, with closing expected in 2H 2026 pending approvals. #M&A
The deal is likely to cap TBPH near the offer price while leaving modest contingent upside, with limited near-term catalyst risk until the transaction closes
Similar Companies in Healthcare
Other companies in the same sector with AI ratings